Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 8933 results

  1. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

    In development Reference number: GID-TA11333 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  3. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  4. Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  5. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  6. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    Awaiting development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development Reference number: GID-DG10083 Expected publication date: TBC

    Diagnostics guidance
    In development

  9. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-DG10038 Expected publication date: TBC

    Diagnostics guidance
    In development

  10. Ex-situ machine perfusion devices for deceased donor liver transplants

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

    Health technology evaluations
    In development

  11. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

    Technology appraisal guidance
    In development

  14. Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]

    In development Reference number: GID-TA11767 Expected publication date:  04 November 2026

    Technology appraisal guidance
    In development

  15. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development